| INTRODUC TI ON
With the increasing number of immunosuppressed patients and significant emergence of opportunistic pathogens, [1] [2] [3] invasive fungal infections caused by Candida species and other yeasts have continuously increased over the last decade. [4] [5] [6] The treatment guideline for candida infection including candidemia, candiduria, vulvovaginal candidiasis, and invasive infections have been revised in 2016. 7 Because antifungal drug susceptibility or resistance varies among species, accurate identification and rapid identification play an important role in selecting antifungal treatment options. 8 Because of the limited treatment choices and high rate of therapeutic failures, novel strategies are needed to improve patient outcomes. 9, 10 Conventional identification of yeast is based on morphology and biochemical tests using its ability to metabolize different sugars and related compounds. Such methods take approximately 24-72 hours and often fail to accurately identify emerging or cryptic species.
11
Molecular identification by sequencing of genomic regions is considered a standard method for identifying yeast to the species level. 12 However, molecular identification remains expensive, time-consuming, and relatively labor-intensive to perform in clinical microbiology laboratories. 13, 14 Due to the above limitations, the introduction of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has been currently in the spotlight and has greatly improved the routine identification of yeast as well as bacteria at species level in the last few years. 4, 8, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] In the present study, we assessed the performance of the ASTA MALDI-TOF MS system in the identification of yeast species from a collection of 284 isolates, in comparison with the performance of molecular identification and biochemical assays. (12, 4 .2%), catheter tips (9, 3.2%), body fluid (7, 2.5%), wounds (7, 2.5%), stool (3, 1.1%), and tissue (1, 0.04%).
| MATERIAL S AND ME THODS

| Clinical samples
All specimens were from immunocompromised patients diagnosed as malignancy (n = 83), chronic respiratory disease (n = 60), neurologic disease (n = 38), diabetes mellitus (n = 30), infectious diseases (n = 21), chronic kidney disease (n = 9), organ transplantation (n = 5), liver disease (n = 5), autoimmune disease (n = 4), HIV 
| MALDI-TOF analysis
Before being processed for MS identification, each isolate was Candida albicans ATCC 64548 were used as control strains.
| Sequencing
All isolates were further identified by sequencing the internal transcribed spacer (ITS) using ITS1 (5′-TCC GTA GGT GAA CCT GCG G-3′) and ITS4 (5′-TCC TCC GCT TAT TGA TAT GC-3′) primers 25 and/or the D1/D2 domains of 28S ribosomal DNA using LR0R (5′-GTA CCC GCT GAA CTT AAG C-3′) 26 and LR5 (5′-ATC CTG AGG GAA ACT TC-3′) primers. 27 The sequences obtained were compared with GenBank data using the BLAST alignment software (blast.ncbi.nlm.nih.gov) and the CBS yeast database (www.cbs.
knaw.nl). A threshold of ≥99% homology was used for identification to the species level.
| Interpretation of the results
Molecular sequencing was considered the gold standard method in our evaluation. The final identification using ASTA MALDI-TOF MS was done as follows. Identification to the species level was done when the results had good confidence levels (score ≥140) or duplicate results showed the same species-level identification although the score was <140. When one of the results was invalid, or duplicate results
showed discrepancies, we considered the identification as a failure.
| Statistical analysis
Chi-square test or Fisher's exact test was used for analyzing differences in the identification rate. Receiver operating characteristic (ROC) curve analysis was used to verify the efficiency of MALDI-TOF MS All P values were two-sided, and the statistical significance threshold was set at P < 0.05. Statistical analysis was performed with MedCalc version 15.5 (MedCalc, Mariakerke, Belgium).
| RE SULTS
The total of 284 isolates was identified as belonging to 14 dif- 
| D ISCUSS I ON
In the present study, we tested the diagnostic performance of a newly developed commercially available ASTA MALDI-TOF MS system for the identification of yeast species, in comparison with that of molecular sequencing. In previous reports comparing MALDI-TOF MS systems with molecular sequencing, the sequencing with only using yeast isolates showed the results inconsistent with those of F I G U R E 1 Assessment of the effectiveness of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based identification of yeast species using composite correlation index (CCI) generated using MALDI-TOF MS A, Clustering analysis was performed based on mass bin profiles. B, A heat map was generated using the Spearman correlation method, and hierarchical clustering was performed by Ward.d2, using the software R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria)
TA B L E 2 List of isolates whose identification showed discrepancies or errors by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (N = 14)
Molecular identification
MALDI-TOF MS
other MALDI-TOF MS systems or biochemical tests. On the other hand, 14 isolates showed disconcordant/invalid results compared with molecular sequencing, of which five isolates of C. glabrata with a score ≥140 were misidentified as C. albicans.
In addition, some species appear to be poorly represented in databases. Among nine isolates showing disconcordant/invalid results with a score <140, the newly emerging, multidrug-resistant C. auris was incorrectly represented as Pichia alni or showed invalid results.
Therefore, the databases need to be updated with information regarding C. auris, because it has recently received attention around the world due to challenges involving antifungal resistance and identification associated with it. 34 ASTA MALDI-TOF MS also failed to identify one C. orthopsilosis isolate, reporting it as C. parapsilosis.
However, such results are also often seen with the VITEK MS system which has shown problems in distinguishing the C. parapsilosis complex. 4, 21 These two species are thought to be challenging to distinguish using MALDI-TOF MS systems because these systems are based on ribosomal protein spectra. 35 For species with extreme similarity in ribosomal protein sequences, protein mass profiles are also too similar to be effectively distinguished using MALDI-TOF MS systems. In such cases, additional molecular data are eventually required for correct identification.
The specimens we used in this study were those obtained from patients with clinical suspicion of yeast infection. Especially, urine sample was from patients with fever and symptom of urinary tract infection or vulvovaginal candidiasis. 7, 36 The presence of candiduria in the asymptomatic patient usually presents colonization, but our patients had symptom and almost all of them underwent urinary tract instrumentation. 7 However, it was hard to distinguish respiratory specimens from colonization or pathogens as Candida pneumonia is very rare. Biotyper system and the new ASTA MALDI-TOF MS system automatically query spectra without the need for prior input regarding sample information. 20 Therefore, the latter two systems have the probability of misidentification of a yeast isolate as a bacterium, especially if the spectrum of a yeast sample is poorly obtained or is not registered in the database. Unlike bacteria, yeast has a thick and chitinous cell wall, which might interfere with direct smear analysis using MALDI-TOF MS. Therefore, formic acid/acetonitrile extraction is recommended before analysis. 8 For repeated tests, the
Biotyper system recommends in-tube extraction instead of on-plate extraction, while the MALDI-TOF MS and VITEK MS systems recommend only the on-plate method. However, the strategy of yeast identification using ASTA MALDI-TOF MS is simplified based on the on-plate testing method using 70% formic acid. The procedure (70% formic acid and CHCA matrix solution addition followed by smearing with the organism) is a standard procedure in the preparation of all microorganisms. In fact, the identification process involves matching of the acquired spectrum with the previously generated reference database, and sample preparation also requires the same procedure as that used to generate the reference spectrum to ensure accurate identification. Because its turnaround time for sample preparation and spectra acquisition is <10 minutes, the on-plate extraction method using formic acid would be a simpler and time-saving method in clinical microbiology laboratories to minimize additional prescreening of microorganisms.
In conclusion, ASTA MALDI-TOF MS has proven to be a rapid, highly accurate, and cost-effective method for the identification of most yeast species isolated from clinical specimens. The new MALDI-TOF MS is a reliable and convenient system for yeast identification and is expected to be useful in clinical microbiology laboratories. 
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